Hepatic arterial embolization with microencapsulated mitomycin C for unresectable hepatocellular carcinoma in cirrhosis

R. A. Audisio, R. Doci, V. Mazzaferro, L. Bellegotti, M. Tommasini, F. Montalto, A. Marchiano, A. Piva, C. DeFazio, B. Damascelli, L. Gennari, D. H. Van Thiel

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

From 1986 to 1988, 35 patients with a hepatoma judged either inoperable or unresectable because of coexistent cirrhosis were treated with hepatic arterial embolization of mitomycin C microcapsules. Five of these 35 patients (14.5%) could not be treated because of inability to selectively cannulate the hepatic artery and were therefore excluded from the evaluation (feasibility rate, 86%). There were 24 men and six women with a median age of 57 years (range, 47 to 79) who could be classified as Okuda I (14 pts) or Okuda II (16 pts) and Child Class A:18 and Child Class B:12 in the remaining patients. A median dose of 0.5 mg mitomycin C/kg was administered to each subject and the treatment was repeated at 5 to 6 week intervals. Seventy courses were administered to these 30 patients (median, two courses/patient; range, 1 to 4). Minor complications were frequent (63%) but always either resolved spontaneously or after appropriate medical treatment. Neither severe renal nor hepatic toxicity was observed. No specific treatment related mortality was observed. When alpha-fetoprotein levels and tumor volume were assessed to evaluate the response to treatment using established criteria for identifying a response, an objective response was found in 43% of the cases treated. The actuarial median survival was 7 months and the 1-year actuarial survival was 36% (51% for those rated as Child Class A and 0% for those identified as Child Class B, P = 0.04 and 78% rated as Okuda Types I and 0% Okuda type II, P = 0.0001). The excellent quality of life and the increased survival rate experienced after mitomycin C microcapsule embolization suggest that this treatment modality can be used successfully in patients seen in the West who have unresectable hepatoma.

Original languageEnglish
Pages (from-to)228-236
Number of pages9
JournalCancer
Volume66
Issue number2
DOIs
Publication statusPublished - 1990

Fingerprint

Mitomycin
Hepatocellular Carcinoma
Fibrosis
Liver
Capsules
Therapeutics
Survival
Hepatic Artery
alpha-Fetoproteins
Tumor Burden
Survival Rate
Quality of Life
Kidney
Mortality

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Hepatic arterial embolization with microencapsulated mitomycin C for unresectable hepatocellular carcinoma in cirrhosis. / Audisio, R. A.; Doci, R.; Mazzaferro, V.; Bellegotti, L.; Tommasini, M.; Montalto, F.; Marchiano, A.; Piva, A.; DeFazio, C.; Damascelli, B.; Gennari, L.; Van Thiel, D. H.

In: Cancer, Vol. 66, No. 2, 1990, p. 228-236.

Research output: Contribution to journalArticle

Audisio, R. A. ; Doci, R. ; Mazzaferro, V. ; Bellegotti, L. ; Tommasini, M. ; Montalto, F. ; Marchiano, A. ; Piva, A. ; DeFazio, C. ; Damascelli, B. ; Gennari, L. ; Van Thiel, D. H. / Hepatic arterial embolization with microencapsulated mitomycin C for unresectable hepatocellular carcinoma in cirrhosis. In: Cancer. 1990 ; Vol. 66, No. 2. pp. 228-236.
@article{5a9a21d6a489431088ec49ab28ea0fbb,
title = "Hepatic arterial embolization with microencapsulated mitomycin C for unresectable hepatocellular carcinoma in cirrhosis",
abstract = "From 1986 to 1988, 35 patients with a hepatoma judged either inoperable or unresectable because of coexistent cirrhosis were treated with hepatic arterial embolization of mitomycin C microcapsules. Five of these 35 patients (14.5{\%}) could not be treated because of inability to selectively cannulate the hepatic artery and were therefore excluded from the evaluation (feasibility rate, 86{\%}). There were 24 men and six women with a median age of 57 years (range, 47 to 79) who could be classified as Okuda I (14 pts) or Okuda II (16 pts) and Child Class A:18 and Child Class B:12 in the remaining patients. A median dose of 0.5 mg mitomycin C/kg was administered to each subject and the treatment was repeated at 5 to 6 week intervals. Seventy courses were administered to these 30 patients (median, two courses/patient; range, 1 to 4). Minor complications were frequent (63{\%}) but always either resolved spontaneously or after appropriate medical treatment. Neither severe renal nor hepatic toxicity was observed. No specific treatment related mortality was observed. When alpha-fetoprotein levels and tumor volume were assessed to evaluate the response to treatment using established criteria for identifying a response, an objective response was found in 43{\%} of the cases treated. The actuarial median survival was 7 months and the 1-year actuarial survival was 36{\%} (51{\%} for those rated as Child Class A and 0{\%} for those identified as Child Class B, P = 0.04 and 78{\%} rated as Okuda Types I and 0{\%} Okuda type II, P = 0.0001). The excellent quality of life and the increased survival rate experienced after mitomycin C microcapsule embolization suggest that this treatment modality can be used successfully in patients seen in the West who have unresectable hepatoma.",
author = "Audisio, {R. A.} and R. Doci and V. Mazzaferro and L. Bellegotti and M. Tommasini and F. Montalto and A. Marchiano and A. Piva and C. DeFazio and B. Damascelli and L. Gennari and {Van Thiel}, {D. H.}",
year = "1990",
doi = "10.1002/1097-0142(19900715)66:2<228::AID-CNCR2820660206>3.0.CO;2-G",
language = "English",
volume = "66",
pages = "228--236",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - Hepatic arterial embolization with microencapsulated mitomycin C for unresectable hepatocellular carcinoma in cirrhosis

AU - Audisio, R. A.

AU - Doci, R.

AU - Mazzaferro, V.

AU - Bellegotti, L.

AU - Tommasini, M.

AU - Montalto, F.

AU - Marchiano, A.

AU - Piva, A.

AU - DeFazio, C.

AU - Damascelli, B.

AU - Gennari, L.

AU - Van Thiel, D. H.

PY - 1990

Y1 - 1990

N2 - From 1986 to 1988, 35 patients with a hepatoma judged either inoperable or unresectable because of coexistent cirrhosis were treated with hepatic arterial embolization of mitomycin C microcapsules. Five of these 35 patients (14.5%) could not be treated because of inability to selectively cannulate the hepatic artery and were therefore excluded from the evaluation (feasibility rate, 86%). There were 24 men and six women with a median age of 57 years (range, 47 to 79) who could be classified as Okuda I (14 pts) or Okuda II (16 pts) and Child Class A:18 and Child Class B:12 in the remaining patients. A median dose of 0.5 mg mitomycin C/kg was administered to each subject and the treatment was repeated at 5 to 6 week intervals. Seventy courses were administered to these 30 patients (median, two courses/patient; range, 1 to 4). Minor complications were frequent (63%) but always either resolved spontaneously or after appropriate medical treatment. Neither severe renal nor hepatic toxicity was observed. No specific treatment related mortality was observed. When alpha-fetoprotein levels and tumor volume were assessed to evaluate the response to treatment using established criteria for identifying a response, an objective response was found in 43% of the cases treated. The actuarial median survival was 7 months and the 1-year actuarial survival was 36% (51% for those rated as Child Class A and 0% for those identified as Child Class B, P = 0.04 and 78% rated as Okuda Types I and 0% Okuda type II, P = 0.0001). The excellent quality of life and the increased survival rate experienced after mitomycin C microcapsule embolization suggest that this treatment modality can be used successfully in patients seen in the West who have unresectable hepatoma.

AB - From 1986 to 1988, 35 patients with a hepatoma judged either inoperable or unresectable because of coexistent cirrhosis were treated with hepatic arterial embolization of mitomycin C microcapsules. Five of these 35 patients (14.5%) could not be treated because of inability to selectively cannulate the hepatic artery and were therefore excluded from the evaluation (feasibility rate, 86%). There were 24 men and six women with a median age of 57 years (range, 47 to 79) who could be classified as Okuda I (14 pts) or Okuda II (16 pts) and Child Class A:18 and Child Class B:12 in the remaining patients. A median dose of 0.5 mg mitomycin C/kg was administered to each subject and the treatment was repeated at 5 to 6 week intervals. Seventy courses were administered to these 30 patients (median, two courses/patient; range, 1 to 4). Minor complications were frequent (63%) but always either resolved spontaneously or after appropriate medical treatment. Neither severe renal nor hepatic toxicity was observed. No specific treatment related mortality was observed. When alpha-fetoprotein levels and tumor volume were assessed to evaluate the response to treatment using established criteria for identifying a response, an objective response was found in 43% of the cases treated. The actuarial median survival was 7 months and the 1-year actuarial survival was 36% (51% for those rated as Child Class A and 0% for those identified as Child Class B, P = 0.04 and 78% rated as Okuda Types I and 0% Okuda type II, P = 0.0001). The excellent quality of life and the increased survival rate experienced after mitomycin C microcapsule embolization suggest that this treatment modality can be used successfully in patients seen in the West who have unresectable hepatoma.

UR - http://www.scopus.com/inward/record.url?scp=0025367024&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025367024&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19900715)66:2<228::AID-CNCR2820660206>3.0.CO;2-G

DO - 10.1002/1097-0142(19900715)66:2<228::AID-CNCR2820660206>3.0.CO;2-G

M3 - Article

C2 - 2164435

AN - SCOPUS:0025367024

VL - 66

SP - 228

EP - 236

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 2

ER -